Quick Answer
Vistagen Therapeutics, Inc. reported Stockholders Equity of $70.39 million for the year ending 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -38.4% in Stockholders Equity from 2024 to 2025.
- This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$12.80 million | Q2 2013: -$11.95 million | Q3 2013: -$12.75 million | Q4 2013: -$11.67 million | Q2 2014: -$15.39 million | Q3 2014: -$17.37 million | Q4 2014: -$17.78 million | Q2 2015: -$2.87 million | Q3 2015: -$1.32 million | Q4 2015: -$1.60 million | Q2 2016: $6.16 million | Q3 2016: $4.09 million | Q4 2016: $2.59 million | Q2 2017: -$606.8 thousand | Q3 2017: -$1.67 million | Q4 2017: $10.26 million | Q2 2018: $3.22 million | Q3 2018: $3.99 million | Q4 2018: $1.69 million | Q2 2019: $1.63 million | Q3 2019: -$3.63 million | Q4 2019: -$6.09 million | Q2 2020: -$5.61 million | Q3 2020: $4.22 million | Q4 2020: $93.81 million | Q2 2021: $85.62 million | Q3 2021: $80.66 million | Q4 2021: $79.98 million | Q2 2022: $46.05 million | Q3 2022: $29.61 million | Q4 2022: $20.67 million | Q2 2023: $6.85 million | Q3 2023: $35.65 million | Q4 2023: $123.29 million | Q1 2024: $114.29 million | Q2 2024: $104.80 million | Q3 2024: $92.97 million | Q4 2024: $81.12 million | Q1 2025: $70.39 million | Q2 2025: $56.77 million | Q3 2025: $66.34 million | Q4 2025: $50.92 million.
- Over the full 19 years of available data (2007 to 2025), Vistagen Therapeutics, Inc.'s Stockholders Equity has grown by 503.4%.
- Historical annual values: Fiscal year 2025: $70.39 million | Fiscal year 2024: $114.29 million | Fiscal year 2023: $12.08 million | Fiscal year 2022: $64.72 million | Fiscal year 2021: $91.98 million | Fiscal year 2020: -$5.73 million | Fiscal year 2019: $7.08 million | Fiscal year 2018: $6.92 million | Fiscal year 2017: $615.8 thousand | Fiscal year 2016: -$2.98 million | Fiscal year 2015: -$20.54 million | Fiscal year 2014: -$12.80 million | Fiscal year 2013: -$12.56 million | Fiscal year 2012: -$5.71 million | Fiscal year 2011: -$32.88 million | Fiscal year 2010: -$26.34 million | Fiscal year 2009: -$26.68 million | Fiscal year 2008: -$22.17 million | Fiscal year 2007: -$17.45 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: